Cardiff Oncology, Inc. (CRDF) has provided an announcement.
On February 29, 2024, a company made significant strides in the fight against metastatic colorectal cancer by releasing promising data from its ONSEMBLE trial and commencing a Phase 2 trial (CRDF-004) with the first patient being dosed. These developments, which are not considered filed under SEC regulations, offer hope for advancements in cancer treatment and highlight the company’s ongoing commitment to addressing this challenging disease.
See more insights into CRDF stock on TipRanks’ Stock Analysis page.
